Thermo Fisher Scientific is a global leader in providing scientific instruments, reagents, and consumables, with a focus on advancing healthcare, life sciences, and laboratory workflows. The company supports a diverse range of customers, including researchers, clinical laboratories, and pharmaceutical companies, by offering innovative solutions that enable breakthroughs in areas such as diagnostics, drug development, and environmental analysis. With a commitment to quality and efficiency, Thermo Fisher Scientific plays a crucial role in enhancing productivity and scientific discovery across various disciplines while promoting better health outcomes worldwide. Read More
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 12.7%. This performance was worse than the S&P 500’s 7.5% fall.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will invest an additional $2 billion in the United States over the next four years, strengthening American innovation, manufacturing and economic competitiveness across the life sciences sector.
Life sciences company Thermo Fisher (NYSE:TMO) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales were flat year on year at $10.36 billion. Its non-GAAP profit of $5.15 per share was 0.9% above analysts’ consensus estimates. The stock remained flat at $433.50 following the earnings release and call.
Thermo Fisher cut its 2025 EPS and revenue outlook due to tariffs and U.S. policy changes, expecting a $400 million sales hit and lower operating income.
The company now expects 2025 revenue to be in the range of $43.3 billion to $44.2 billion and adjusted EPS to be in the range of $21.76 to $22.84, compared with its previous forecast of $23.10 to $23.50.
Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration helped lift investor confidence.
Life sciences company Thermo Fisher (NYSE:TMO) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $10.36 billion. Its non-GAAP profit of $5.15 per share was 0.9% above analysts’ consensus estimates.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025.
Let’s dig into the relative performance of Mettler-Toledo (NYSE:MTD) and its peers as we unravel the now-completed Q4 research tools & consumables earnings season.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2025 before the market opens on Wednesday, April 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET.
Solventum detailed its 2025-2028 growth strategy, reaffirmed its 2025 guidance, and reported Q4 earnings that topped expectations with strong sales and EPS.
